VOLUNTEER and download this list of 47 USA Stage 3 Clinical Test Sites for AnnovisBio.com "MIRACLE" (we hope!) Drug!

[PDWarrior1900]

I just got the latest list of 47 Stage 3 test sites for a VERY promising new drug!

You can volunteer!

You're welcome to download it from the link below.

STAY STRONG! A 'MIRACLE CURE' is just around the corner!

------------------------------------------------------------------

"Buntanetap (previously known as ANVS401 or Posiphen) is our lead compound. It is a translational inhibitor of neurotoxic aggregating proteins (TINAPs). Different from monoclonal antibody therapies, buntanetap is an orally available small molecule, and its unique mechanism of action allows it to inhibit multiple neurotoxic proteins at once. Recent research has shown that multiple neurotoxic proteins are at play in all neurodegenerative diseases."

"Buntanetap, thus, offers a transformative and superior mechanism to treat neurodegenerative disorders. It’s being developed for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions such as Alzheimer’s in Down syndrome."

annovisbio.com/

docs.google.com/spreadsheet...

[Hidden]

youtu.be/qUvNzBxq3cY(Not working as expected?)

[Hidden]

youtu.be/Za4wiI64Eko(Not working as expected?)

[park_bear in reply to Hidden]

Interview notes:

"Cheng Fang, PhD, Annovis Bio, Berwyn, PA, explains the unique mechanism of action of investigational small molecule, buntanetap. Buntanetap is an orally available agent, acting as a translational inhibitor of neurotoxic aggregating proteins. It acts on the iron response element in the 5′-untranslated region of mRNA that is preserved among neurotoxic aggregating proteins. Buntanetap increases the affinity of iron regulatory protein 1 (IRP1) to IRE, preventing association with the ribosome and thus, inhibiting translation. Buntanetap has been shown to inhibit the translation of multiple neurotoxic proteins such as amyloid precursor protein, tau and alpha-synuclein. In preclinical models, buntanetap was able to restore axonal transport, lower inflammation and protect against cell death. Its mechanism of action makes it a promising candidate in several neurodegenerative diseases where toxic protein aggregation and accumulation is at play. It is currently being developed for Alzheimer’s disease (AD) and Parkinson’s disease (PD), showing improvement in cognition in patients with AD and motor function in patients with PD in Phase II studies. This interview took place at the Alzheimer's Association International Conference (AAIC) 2022 in San Diego, CA."

[RonB1 in reply to park_bear]

This actually sounds promising as there is some semblance of hope here. Thank you for the thorough analysis on Buntanetap.

[park_bear in reply to RonB1]

Thanks but cannot take credit - was just a copy and paste from YouTube.

[RonB1 in reply to park_bear]

Perhaps yes, however I have been following you posts for a few months and I really appreciate your thorough and comprehensive articles.

[jeffreyn]

Only 20 sites are currently recruiting. These 20 sites are listed under "Locations" in the study record, as of 1 Nov 2022.

clinicaltrials.gov/ct2/show...

[slimweiss]

I just emailed them. We shall see! We live in Oceanside so not far from Orange Co.